User profiles for SILVIA MEZI
 | Silvia Mezisapienza universita' di roma Verified email at uniroma1.it Cited by 2131 |
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and …
…, C Antoniotti, C Lupi, E Sensi, S Lonardi, S Mezi… - The Lancet …, 2015 - thelancet.com
Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and
irinotecan) plus bevacizumab significantly improved progression-free survival of patients with …
irinotecan) plus bevacizumab significantly improved progression-free survival of patients with …
[HTML][HTML] Anti–PD-1 and anti–PD-L1 in head and neck cancer: a network meta-analysis
Objective The monoclonal antibodies anti-programmed death protein-1 (anti–PD-1)
nivolumab and pembrolizumab are the first immune checkpoint inhibitors (ICIs) approved for …
nivolumab and pembrolizumab are the first immune checkpoint inhibitors (ICIs) approved for …
[HTML][HTML] The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy
Immune checkpoint inhibitors have revolutionized treatment and outcome of melanoma and
many other solid malignancies including non-small cell lung cancer (NSCLC) and renal cell …
many other solid malignancies including non-small cell lung cancer (NSCLC) and renal cell …
Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials
Background. mTOR inhibitors are currently used in the treatment of solid malignancies. Since
their approval, several cases of pulmonary toxicity (PT) have been described. This analysis …
their approval, several cases of pulmonary toxicity (PT) have been described. This analysis …
[HTML][HTML] Tobacco, alcohol and family history of cancer as risk factors of Oral Squamous Cell Carcinoma: Case-control retrospective study
…, D Musio, CRT Di Gioia, D Messineo, S Mezi… - Applied Sciences, 2020 - mdpi.com
The aim of the study is to observe retrospectively the correlation between Oral Squamous
Cell Carcinoma (OSCC) and risk factors; including tobacco, alcohol and Family History of …
Cell Carcinoma (OSCC) and risk factors; including tobacco, alcohol and Family History of …
Incidence and relative risk of hepatic toxicity in patients treated with anti‐angiogenic tyrosine kinase inhibitors for malignancy
…, P Trenta, A De Benedetto, S Mezi… - British journal of …, 2014 - Wiley Online Library
Aim The aim of this study is to investigate the incidence and risk of hepatic toxicity in patients
receiving tyrosine kinase inhibitors ( TKIs ) through a large up‐to‐date meta‐analysis of …
receiving tyrosine kinase inhibitors ( TKIs ) through a large up‐to‐date meta‐analysis of …
Follow-up program in head and neck cancer
…, M de Vincentiis, V Valentini, D Musio, S Mezi… - Critical Reviews in …, 2017 - Elsevier
… Author links open overlay panel Francesca De Felice a , Marco de Vincentiis b , Valentino
Valentini c , Daniela Musio a , Silvia Mezi d , Luigi Lo Mele e , Valentina Terenzi c , Vittorio D’…
Valentini c , Daniela Musio a , Silvia Mezi d , Luigi Lo Mele e , Valentina Terenzi c , Vittorio D’…
[HTML][HTML] The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study
…, F Scirocchi, A Rughetti, M Nuti, S Mezi… - Journal of Personalized …, 2021 - mdpi.com
Unresectable recurrent and/or metastatic head and neck squamous cell carcinoma (R/M
HNSCC) has a very poor prognosis. Soluble immune checkpoints (sICs) are circulating proteins …
HNSCC) has a very poor prognosis. Soluble immune checkpoints (sICs) are circulating proteins …
[HTML][HTML] The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy
Background Despite the efficacy of immunotherapy, only a small percentage of patients
achieves a long-term benefit in terms of overall survival. The aim of this study was to define an …
achieves a long-term benefit in terms of overall survival. The aim of this study was to define an …
[HTML][HTML] Tryptophan catabolism as immune mechanism of primary resistance to anti-PD-1
A Botticelli, S Mezi, G Pomati, B Cerbelli… - Frontiers in …, 2020 - frontiersin.org
Background: Clinical trials showed that only a subset of patients benefits from immunotherapy,
suggesting the need to identify new predictive biomarker of resistance. Indoleamine-2,3-…
suggesting the need to identify new predictive biomarker of resistance. Indoleamine-2,3-…